首页 > 市场调查报告书 > 製药

感染疾病

市场调查报告书

商品编码

1566194

HIV 药物市场规模、份额、成长分析，按药物类别、分销管道、地区划分 - 产业预测，2024-2031 年

HIV Drugs Market Size, Share, Growth Analysis, By Medication Class (Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors), By Distribution Channel (Hospital Pharmacies, Hospital Pharmacies), By Region - Industry Forecast 2024-2031

出版日期: 2024年10月03日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年全球爱滋病药物市场规模为316亿美元，从2023年的345.7亿美元成长到2031年的709.3亿美元，在预测期内（2024-2031年）预计复合年增长率为9.4。

HIV胶囊市场是製药业的重要组成部分，为爱滋病毒/爱滋病患者提供挽救生命的治疗。近年来，由于医疗技术的进步以及对爱滋病毒预防和治疗的日益重视，该市场经历了显着增长。推动市场扩张的主要因素包括爱滋病毒/爱滋病盛行率的增加、医疗保健服务的改善以及持续的研究和发展。推动市场的主要因素是抗逆转录病毒疗法（ART）的需求，它仍然是爱滋病毒/爱滋病的标准治疗方法。 ART 有效降低病毒量，增强免疫功能，有助于预防病毒传播。展望2022年和2023年，受多种因素影响，市场预计将持续呈上升趋势。爱滋病毒/爱滋病患者数量的增加，特别是在新兴国家，预计将推动爱滋病毒药物的需求。此外，持续研究和开发更有效的新药物，包括长效注射治疗的进展，预计也将塑造市场。儘管 COVID-19 大流行扰乱了供应链和医疗保健系统，但我们正在努力确保爱滋病毒治疗和预防服务的连续性，并帮助减轻对爱滋病毒药物市场的影响。

市场概况
多重药物合併用药
- 阿特里普拉
- 康普雷拉
- 普雷兹科维克斯
- 斯特里构建
- 玄博屋
- 奥德布塞
- 辛图札
- 特里梅克
- 德斯科比
- 多瓦托
- 其他的
核苷逆转录酶抑制剂（NRTI）
- 姆特里巴
- 依匹韦
- Epzicom/Kibexa
- 特鲁巴达
- 胜利
- 其他的
非核苷类逆转录酶抑制剂（NNRTI）
- 教育者
- 其他的
蛋白酶抑制剂 (PI)
- 阿普蒂总线
- 克力芝
- 莱克西瓦/泰尔齐尔
- 诺维尔
- 维拉西普
- 其他的
侵袭抑制剂
- 塞尔岑特里
- 融合
- 卢科维亚
HIV整合酶链转移抑制剂
- Eyesentless/Isentless HD
- 蒂比凯
- 光圈
- 尤尔卡
其他的

HIV药物市场：依分销管道分类

市场概况
医院药房
药局和药局零售
网路药房

HIV 药物市场：按地区分類的规模

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲国家地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- 其他中东/非洲地区

竞争格局

前5名企业对比
主要企业市场定位（2023年）
主要市场参与者所采取的策略
近期市集活动
主要企业市场占有率（2023年）

主要企业简介

Gilead Sciences, Inc.（US）
AbbVie Inc.（US）
Bristol-Myers Squibb Company（US）
Johnson & Johnson（US）
GlaxoSmithKline plc（UK）
Teva Pharmaceutical Industries Ltd.（Israel）
F. Hoffmann-La Roche Ltd.（Switzerland）
Merck & Co., Inc.（US）
Boehringer Ingelheim International GmbH（Germany）
Cipla Ltd.（India）
ViiV Healthcare（UK）
AstraZeneca plc（UK）
Hikma Pharmaceuticals PLC（UK）
Abbott Laboratories（US）
Eli Lilly and Company（US）
Alvogen（US）
Aurobindo Pharma（India）
Mundipharma（Switzerland）
Sanofi SA（France）
Novartis AG（Switzerland）
Dr. Reddy's Laboratories（India）
Zydus Cadila（India）
Perrigo Company plc（Ireland）

简介目录

Product Code: SQMIG35I2310

Global HIV Drugs Market size was valued at USD 31.6 billion in 2022 and is poised to grow from USD 34.57 billion in 2023 to USD 70.93 billion by 2031, growing at a CAGR of 9.4% during the forecast period (2024-2031).

The HIV capsules market is a vital sector within the pharmaceutical industry, providing life-saving treatments for individuals living with HIV/AIDS. This market has experienced considerable growth in recent years due to advancements in medical technology and a heightened emphasis on HIV prevention and treatment. Key drivers of market expansion include the increasing prevalence of HIV/AIDS, improved access to healthcare services, and ongoing research and development efforts. The primary factor propelling the market is the demand for antiretroviral therapy (ART), which remains the standard treatment for HIV/AIDS. ART effectively reduces viral load, boosts immune function, and helps prevent virus transmission. Looking ahead to 2022 and 2023, the market is expected to continue its upward trend, influenced by several factors. The rising number of HIV/AIDS cases, especially in developing countries, is anticipated to drive demand for HIV medications. Additionally, ongoing research and the development of new, more effective drugs, including advancements in long-acting injectable treatments, are likely to shape the market. While the COVID-19 pandemic has caused some disruptions in supply chains and healthcare systems, efforts are underway to ensure the continuity of HIV treatment and prevention services, helping to mitigate the impact on the HIV drugs market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global HIV Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global HIV Drugs Market Segmental Analysis

Global HIV Drugs Market is segmented by Medication Class, Distribution Channel. Based on Medication Class, the market is segmented into Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Entry Inhibitors, HIV Integrase Strand Transfer Inhibitors, and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drugs stores and retail pharmacies, Online pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Drivers of the Global HIV Drugs Market

The persistently high global prevalence of HIV/AIDS is a major driver for the ongoing demand for antiretroviral medications. Supportive government initiatives, particularly in developing nations, along with international funding programs, play a crucial role in market growth by enhancing accessibility to these vital treatments. The Asia-Pacific region, in particular, is experiencing rapid market growth due to advancements in health awareness, improvements in healthcare infrastructure, and the increasing number of hospitals and ambulatory surgical centers equipped with advanced medical facilities. Ongoing research and development efforts are leading to the discovery of new and more effective antiretroviral drugs, further stimulating market expansion. Increased awareness and proactive testing initiatives are also contributing to early detection and a higher demand for HIV medications. Additionally, global collaborations between governments, non-profit organizations, and pharmaceutical companies aim to address the challenges of HIV/AIDS, supporting market growth and improving treatment outcomes.

Restraints in the Global HIV Drugs Market

Access to HIV medications remains a significant challenge, particularly in developing regions where affordability issues can hinder patients' ability to obtain essential treatments. In addition, stigma associated with HIV/AIDS in various societies can obstruct awareness campaigns, deter testing, and reduce patient adherence to treatment regimens. The presence of generic versions of certain HIV drugs further complicates market dynamics, especially in areas where cost-effectiveness is a critical factor. Additionally, inadequate healthcare infrastructure in many developing countries can impede the efficient distribution and administration of HIV medications, affecting market growth. The emergence of drug-resistant HIV strains also challenges the effectiveness of current antiretroviral treatments, underscoring the need for ongoing research and development to address these evolving issues.

Market Trends of the Global HIV Drugs Market

A notable trend in HIV treatment is the development and adoption of single-tablet regimens that combine multiple antiretroviral medications into one pill. This approach streamlines treatment protocols, enhancing patient adherence and convenience by reducing the complexity of medication schedules. Such single-tablet regimens make managing HIV treatment more straightforward, contributing to better adherence and overall patient satisfaction. By consolidating several medications into one convenient form, these regimens not only simplify the treatment process but also improve the effectiveness of therapy by ensuring consistent medication use.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Pricing Analysis
Value Chain Analysis
Ecosystem of the Market
Trade Analysis
Supply chain Analysis
Case study Analysis
Patent Analysis
Customer & Buying Criteria Analysis
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Degree of Competition

HIV Drugs Market by Medication Class

Market Overview
Multi-Class Combination Drugs
- Atripla
- Complera
- Prezcobix
- Stribild
- Genvoya
- Odefsey
- Symtuza
- Triumeq
- Descovy
- Dovato
- Others
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- Emtriva
- Epivir
- Epzicom/Kivexa
- Truvada
- Biktarvy
- Others
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- Edurant
- Others
Protease Inhibitors (PIs)
- Aptivus
- Kaletra
- Lexiva/ Telzir
- Norvir
- Viracept
- Others
Entry Inhibitors
- Selzentry
- Fuzeon
- Rukobia
HIV Integrase Strand Transfer Inhibitors
- Isentress/Isentress HD
- Tivicay
- Apretude
- Juluca
Others

HIV Drugs Market by Distribution Channel

Market Overview
Hospital Pharmacies
Drugs stores and retail pharmacies
Online pharmacies

HIV Drugs Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Gilead Sciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim International GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ViiV Healthcare (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hikma Pharmaceuticals PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alvogen (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aurobindo Pharma (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mundipharma (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dr. Reddy's Laboratories (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zydus Cadila (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Perrigo Company plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments